240 related articles for article (PubMed ID: 31857119)
1. Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies.
Bublil EM; Majtan T
Biochimie; 2020 Jun; 173():48-56. PubMed ID: 31857119
[TBL] [Abstract][Full Text] [Related]
2. Interplay of Enzyme Therapy and Dietary Management of Murine Homocystinuria.
Park I; Bublil EM; Glavin F; Majtan T
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32971905
[TBL] [Abstract][Full Text] [Related]
3. Potential Pharmacological Chaperones for Cystathionine Beta-Synthase-Deficient Homocystinuria.
Majtan T; Pey AL; Gimenez-Mascarell P; Martínez-Cruz LA; Szabo C; Kožich V; Kraus JP
Handb Exp Pharmacol; 2018; 245():345-383. PubMed ID: 29119254
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cystathionine Beta-Synthase Misfolding in Homocystinuria by Small Ligands: State of the Art and Future Directions.
Majtan T; Pey AL; Ereño-Orbea J; Martínez-Cruz LA; Kraus JP
Curr Drug Targets; 2016; 17(13):1455-70. PubMed ID: 26931358
[TBL] [Abstract][Full Text] [Related]
5. An orally administered enzyme therapeutic for homocystinuria that suppresses homocysteine by metabolizing methionine in the gastrointestinal tract.
Skvorak K; Mitchell V; Teadt L; Franklin KA; Lee HO; Kruse N; Huitt-Roehl C; Hang J; Du F; Galanie S; Guan S; Aijaz H; Zhang N; Rajkovic G; Kruger WD; Ismaili MHA; Huisman G; McCluskie K; Silverman AP
Mol Genet Metab; 2023 Aug; 139(4):107653. PubMed ID: 37463544
[TBL] [Abstract][Full Text] [Related]
6. Derangement of hepatic polyamine, folate, and methionine cycle metabolism in cystathionine beta-synthase-deficient homocystinuria in the presence and absence of treatment: Possible implications for pathogenesis.
Maclean KN; Jiang H; Phinney WN; Mclagan BM; Roede JR; Stabler SP
Mol Genet Metab; 2021 Feb; 132(2):128-138. PubMed ID: 33483253
[TBL] [Abstract][Full Text] [Related]
7. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy.
Majtan T; Park I; Cox A; Branchford BR; di Paola J; Bublil EM; Kraus JP
FASEB J; 2019 Nov; 33(11):12477-12486. PubMed ID: 31450979
[TBL] [Abstract][Full Text] [Related]
8. Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria.
Majtan T; Kožich V; Kruger WD
Br J Pharmacol; 2023 Feb; 180(3):264-278. PubMed ID: 36417581
[TBL] [Abstract][Full Text] [Related]
9. Long-term betaine therapy in a murine model of cystathionine beta-synthase deficient homocystinuria: decreased efficacy over time reveals a significant threshold effect between elevated homocysteine and thrombotic risk.
Maclean KN; Jiang H; Greiner LS; Allen RH; Stabler SP
Mol Genet Metab; 2012 Mar; 105(3):395-403. PubMed ID: 22192524
[TBL] [Abstract][Full Text] [Related]
10. Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria.
Majtan T; Jones W; Krijt J; Park I; Kruger WD; Kožich V; Bassnett S; Bublil EM; Kraus JP
Mol Ther; 2018 Mar; 26(3):834-844. PubMed ID: 29398487
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria.
Majtan T; Hůlková H; Park I; Krijt J; Kožich V; Bublil EM; Kraus JP
FASEB J; 2017 Dec; 31(12):5495-5506. PubMed ID: 28821635
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement with PEGylated cystathionine β-synthase ameliorates homocystinuria in murine model.
Bublil EM; Majtan T; Park I; Carrillo RS; Hůlková H; Krijt J; Kožich V; Kraus JP
J Clin Invest; 2016 Jun; 126(6):2372-84. PubMed ID: 27183385
[TBL] [Abstract][Full Text] [Related]
13. Taurine alleviates repression of betaine-homocysteine
Maclean KN; Jiang H; Phinney WN; Keating AK; Hurt KJ; Stabler SP
FASEB J; 2019 May; 33(5):6339-6353. PubMed ID: 30768359
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta-synthase for treatment of homocystinuria.
Majtan T; Bublil EM; Park I; Arning E; Bottiglieri T; Glavin F; Kraus JP
Life Sci; 2018 May; 200():15-25. PubMed ID: 29526799
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Cystathionine β-Synthase Deficiency in Mice Using a Minicircle-Based Naked DNA Vector.
Lee HO; Gallego-Villar L; Grisch-Chan HM; Häberle J; Thöny B; Kruger WD
Hum Gene Ther; 2019 Sep; 30(9):1093-1100. PubMed ID: 31084364
[TBL] [Abstract][Full Text] [Related]
16. Long-term functional correction of cystathionine β-synthase deficiency in mice by adeno-associated viral gene therapy.
Lee HO; Salami CO; Sondhi D; Kaminsky SM; Crystal RG; Kruger WD
J Inherit Metab Dis; 2021 Nov; 44(6):1382-1392. PubMed ID: 34528713
[TBL] [Abstract][Full Text] [Related]
17. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control.
Yap S; Naughten E
J Inherit Metab Dis; 1998 Oct; 21(7):738-47. PubMed ID: 9819703
[TBL] [Abstract][Full Text] [Related]
18. Characterization of two pathogenic mutations in cystathionine beta-synthase: different intracellular locations for wild-type and mutant proteins.
Casique L; Kabil O; Banerjee R; Martinez JC; De Lucca M
Gene; 2013 Nov; 531(1):117-24. PubMed ID: 23981774
[TBL] [Abstract][Full Text] [Related]
19. Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria.
Keating AK; Freehauf C; Jiang H; Brodsky GL; Stabler SP; Allen RH; Graham DK; Thomas JA; Van Hove JL; Maclean KN
Mol Genet Metab; 2011 Aug; 103(4):330-7. PubMed ID: 21601502
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes.
Jiang H; Stabler SP; Allen RH; Maclean KN
Mol Genet Metab; 2012 Sep; 107(1-2):55-65. PubMed ID: 22633282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
